Back
12.03.2024
Grifols Bond Yield Drops on Auditor Approval of 2023 Results
Grifols Bond Yield Drops on Auditor Approval of 2023 Results
446

Grifols' bond experienced a notable decrease in yield following KPMG's approval of its 2023 results, reassuring investors amidst previous concerns about accounting practices and financial metrics.

The Grifols 3.2% May 2025 EUR bond (XS1598758578) has experienced a notable shift in its yield, dropping by 288 basis points to 7.9% over the course of the week.

Yield curve illustration showing the performance of the Grifols bond (XS1598757760), with a 3.2% coupon, due on May 1, 2025, in Euros.

The substantial decline in the bond's yield follows positive news regarding Spanish pharmaceutical giant Grifols. Shares of Grifols surged by more than 16% after it received approval from auditor KPMG for its 2023 results, which were reported without modifications to the previously stated profit and debt ratio. The approval from KPMG instilled confidence in investors, alleviating concerns that arose from the company's provisional 2023 results and doubts regarding its cash flow for 2024.

Grifols' 2023 results, which were initially published pending an audit, had contributed to uncertainties in the market, exacerbated by a report from short-seller fund Gotham City Research questioning the company's accounting practices and debt ratio. However, with the audit approval and clarification regarding its financial position, Grifols reassured investors by affirming that the integration of a junior venture with firm ImmunoTek, along with a deal to develop 28 plasma collection centers signed in 2021, did not significantly impact its financial metrics.

Despite reporting a 72% decrease in profit for 2023, attributed to restructuring costs, Grifols managed to lower its debt-to-EBITDA ratio to 6.3, indicating improvements in its financial leverage. The company's proactive measures to address concerns and strengthen its financial position have garnered positive investor sentiment, reflected in the notable decrease in the yield of its bonds.

The company's senior unsecured debt is rated as follows: 'BB-' by Fitch, 'B+' by S&P, and 'Caa1' by Moody's.

The Yield Map for Grifols SA Euro-denominated bonds as of March 12, 2024:

The Yield Map for Grifols SA Euro-denominated bonds as of March 12, 2024

About Grifols

Grifols SA, headquartered in Spain, specializes in the manufacturing of biopharmaceuticals. The company operates across four main business segments: Bioscience, Hospital, Diagnostic, and Raw Materials. The Bioscience division is dedicated to researching, developing, manufacturing, and marketing products derived from human plasma for therapeutic purposes. The Hospital division provides non-biological pharmaceutical products and medical supplies to hospital pharmacies. The Diagnostic division supplies clinical analysis and laboratory testing tools to laboratories, hospitals, and blood banks. The Raw Materials division encompasses the sale of intermediate biological products and manufacturing services to third parties. Grifols SA has production facilities in various locations, including Spain, the United States, Mexico, and Australia, and controls several subsidiaries. Grifols SA has a market capitalization of €5.15 billion as of March 08, 2024.

This article does not constitute investment advice or personal recommendation. Past performance is not a reliable indicator of future results. Bondfish does not recommend using the data and information provided as the only basis for making any investment decision. You should not make any investment decisions without first conducting your own research and considering your own financial situation.